Monoclonal Gammopathy of Undetermined Significance - 18 Studies Found
Suspended |
: Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance :
|
Completed |
: Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) :
|
Recruiting |
: Unravel MGUS (Monoclonal Gammopathy of Unknown Significance) : Monoclonal Gammopathy of Unknown Significance : 2016-09-15 :
|
Completed |
: A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma :
|
Completed |
: Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy :
|
Active, not recruiting |
: Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. :
|
Recruiting |
: Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies :
|
Terminated |
: Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance : Precancerous Condition : 2007-12-20 : Biological: Rituximab Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four |
Not yet recruiting |
: Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat :
|